Trials / Completed
CompletedNCT00351832
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 236 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-06-01
- First posted
- 2006-07-13
- Last updated
- 2007-05-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00351832. Inclusion in this directory is not an endorsement.